These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17379099)

  • 1. Recent advances in myelodysplastic syndromes.
    Shadduck RK; Latsko JM; Rossetti JM; Haq B; Abdulhaq H
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):137-43. PubMed ID: 17379099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New agents in myelodysplastic syndromes.
    Jabbour EJ; Giles FJ
    Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias.
    Morgan MA; Reuter CW
    Ann Hematol; 2006 Mar; 85(3):139-63. PubMed ID: 16391911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translational research in myelodysplastic syndromes.
    Raza A; Qawi H; Mehdi M; Mumtaz M; Galili N
    Rev Clin Exp Hematol; 2004 Dec; 8(2):E2. PubMed ID: 16027100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies.
    Giagounidis AA; Germing U; Aul C
    Clin Cancer Res; 2006 Jan; 12(1):5-10. PubMed ID: 16397017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
    List A
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelodysplasia: when to treat and how.
    Larson RA
    Best Pract Res Clin Haematol; 2006; 19(2):293-300. PubMed ID: 16516126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
    Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
    Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of myelodysplastic syndromes in elderly patients.
    Sanchez JF
    Adv Ther; 2011 Mar; 28 Suppl 2():1-9. PubMed ID: 21431504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory drugs in the treatment of myelodysplastic syndromes.
    Ortega J; List A
    Curr Opin Oncol; 2007 Nov; 19(6):656-9. PubMed ID: 17906467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of angiogenesis in the biology and therapy of myelodysplastic syndromes.
    Aguayo A
    Curr Hematol Rep; 2004 May; 3(3):184-91. PubMed ID: 15087066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes.
    Olney HJ; Le Beau MM
    Leuk Res; 2007 Apr; 31(4):427-34. PubMed ID: 17161457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS).
    List AF
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S31-5. PubMed ID: 16085015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.
    Melchert M; Kale V; List A
    Curr Opin Hematol; 2007 Mar; 14(2):123-9. PubMed ID: 17255789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.
    Cilloni D; Messa E; Messa F; Carturan S; Defilippi I; Arruga F; Rosso V; Catalano R; Bracco E; Nicoli P; Saglio G
    Ann N Y Acad Sci; 2006 Nov; 1089():411-23. PubMed ID: 17261784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of angiogenesis in patients with myelodysplastic syndrome.
    Estey EH
    Best Pract Res Clin Haematol; 2004 Dec; 17(4):623-39. PubMed ID: 15494299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel therapeutic agents in acute myeloid leukemia.
    Stone RM
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):163-6. PubMed ID: 17379102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the therapy for myelodysplastic syndrome.
    Kasner MT; Luger SM
    Am J Hematol; 2009 Mar; 84(3):177-86. PubMed ID: 19195035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.